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Supplementary Table 1. Number of Clinically Diagnosed Alzheimer’s Dementia Cases and Controls for Each APOE Genotype 
 
APOE 
Neuropathologically Confirmed  Neuropathologically Unconfirmed  Combined 
Cases Controls Total %  Cases Controls Total %  Cases Controls Total % 
2/2 5 19 24 0.5  16 70 86 0.4  21 89 110 0.4 
2/3 113 147 260 5.2  450 1,610 2060 8.6  563 1,757 2320 8.0 
3/3 1,273 638 1911 38.2  3,604 8,175 11779 49.4  4,877 8,813 13690 47.4 
2/4 107 20 127 2.54  311 286 597 2.5  418 306 724 2.5 
3/4 1,897 155 2052 41.0  4,690 2,998 7688 32.2  6,587 3,153 9740 33.7 
4/4 623 10 633 12.6  288 1,359 1647 6.9  1,982 2,98 1982 6.9 
TOTAL 4,018 989 5007 100  10,430 13,427 23857 100  14,448 14,416 28864 100 
 
This table provides a summary of all cases with the clinical diagnosis of Alzheimer’s dementia and all cognitively unimpaired controls with APOE 
genotypes in the ADGC database. Participants in the combined group consisted of neuropathologically confirmed autopsy and neuropathologically 
unconfirmed clinical subjects, excluding neuropathologically misclassified subjects. Since the ADGC used both clinical and neuropathological criteria 
to prioritize autopsy participants in the ADGC database, the table does not include a substantial number of clinically characterized but 





Supplementary Table 2. Characteristics of Alzheimer’s Dementia Cases and Controls 
 
APOE 
Neuropathologically Confirmed  Neuropathologically Unconfirmed 
AD Cases  Controls  AD Cases  Controls 
AAO AAD % Female  AAD % Female  AAO AAE % Female  AAE % Female 
2/2 74.3 ± 0.8 82.3 ± 7.3 40  85.2 ± 9.0 50  79.3 ± 8.2 81.6 ± 8.4 0.63  77.4 ± 8.2 50 
2/3 79.4 ± 9.0 86.3 ± 8.8 60  83.5 ± 8.4 56  77.2 ± 8.4 80.8 ± 8.1 0.54  77.3 ± 8.0 59 
3/3 77.1 ± 8.9 83.9 ± 8.2 62  82.1 ± 9.0 51  76.3 ± 7.8 80.6 ± 7.6 0.59  76.6 ± 7.9 60 
2/4 74.0 ± 6.1 83.3 ± 7.1 68  82.5 ± 7.8 58  75.2 ± 6.9 79.9 ± 7.1 0.63  75.4 ± 7.5 58 
3/4 73.3 ± 7.2 81.9 ± 7.2 56  80.9 ± 8.1 46  73.3 ± 6.7 78.4 ± 6.7 0.61  74.4 ± 7.6 61 
4/4 69.9 ± 6.1 79.0 ± 6.5 53  79.0 ± 7.6 50  69.5 ± 5.9 75.3 ± 6.7 0.55  72.2 ± 6.7 62 
Total 74.2 ± 8.0 82.3 ± 7.7 58  82.1 ± 8.7 51  74.1 ± 7.4 74.0 ± 7.0 0.59  76.1 ± 7.9 60 
 
The neuropathologically confirmed group contained participants available with clinical diagnosis, the APOE genotype, and an age variable (age at 
dementia onset, age at death, or age at last clinical evaluation). Affection status of cases and controls in the autopsied sample was defined by 
clinical diagnosis. 
The neuropathologically unconfirmed group includes clinically diagnosed but neuropathologically uncharacterized cases and controls. 
AAO: Estimated age at dementia onset (when available) in the Alzheimer’s dementia cases in years.  
Only two APOE2 homozygotes with neuropathologically confirmed Alzheimer’s dementia had an estimated AAO. AAO in the 65 combined APOE2/2 
and 2/3 groups with neuropathologically confirmed Alzheimer’s dementia was 79.3±9.0 years.    
AAD: Age at death in the neuropathologically confirmed cases and controls in years. 
AAE: Age at last clinical evaluation (when available) in the combined cases and controls in years. 
Mean (Mean) and standard deviation (SD) for AAO, AAD, and AAE ranged from Mean-SD and Mean+SD, Mean±SD. 
  
 
Supplementary Table 3. Alzheimer’s Dementia Odds Ratios for Each APOE genotype after Adjustment for Age and Sex 
 
APOE 
Neuropathologically Confirmed  Neuropathologically Unconfirmed 
OR 95% CI P  OR 95% CI P 
Genotype        
2/2 0.16 0.06 - 0.43 3.0x10-4  0.52 0.3 - 0.89 0.018 
2/3 0.40 0.31 - 0.53 3.6x10-11  0.63 0.54 - 0.75 8.6x10-8 
2/4 2.47 1.51 - 4.04 3.4x10-4  2.49 2.05 - 3.04 1.2x10-19 
3/4 5.71 4.71 - 6.92 8.2x10-68  3.55 3.19 - 3.96 2.0x10-115 
4/4 26.93 14.39 - 50.38 2.1x10-24  10.94 9.29 - 12.89 3.2x10-180 
Allelic Dose        
2 0.40 0.32 - 0.51 1.0x10-13  0.64 0.58 - 0.72 1.7x10-15 
4 5.57 4.69 - 6.61 1.3x10-81  3.42 3.24 - 3.60 <10-300 
 
For genotypic association tests, odds ratio (OR), 95% confidence interval (CI), and P value (P) for each APOE genotype compared to the APOE3/3 
genotype were calculated under a logistic regression model. 
For allelic association tests, OR, CI, and P associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2<2/3<3/3) and APOE4 allelic dose 
in APOE2 non-carriers (APOE4/4>3/4>3/3) in an additive genetic model were generated under a logistic regression model.  
 







age and sex adjustment 
 
Model 3 
age, sex and autopsy adjustment 
OR 95% CI P  OR 95% CI P  OR 95% CI P 
Genotype            
2/2 0.43 0.26 - 0.70 7.4x10-4  0.42 0.26 - 0.7 7.1x10-4  0.35 0.20 - 0.61 2.0x10-4 
2/3 0.58 0.52 - 0.64 1.9x10-25  0.58 0.52 - 0.64 3.1x10-25  0.59 0.53 - 0.66 1.1x10-21 
2/4 2.47 2.12 - 2.87 2.7x10-31  2.49 2.14 - 2.90 9.8x10-32  2.49 2.13 - 2.92 3.8x10-30 
3/4 3.78 3.57 – 4.00 <10-300  3.78 3.57 – 4.00 <10-300  3.71 3.49 - 3.94 <10-300 
4/4 12.02 10.58 - 13.66 <10-300  12.28 10.76 - 14.01 <10-300  11.39 9.96 - 13.02 3.1x10-277 
Allelic Dose            
2 0.59 0.53 - 0.65 9.1x10-27  0.59 0.53 - 0.65 1.4x10-26  0.59 0.53 - 0.65 3.1x10-24 
4 3.65 3.48 - 3.82 <10-300  3.64 3.47 - 3.83 <10-300  3.55 3.38 - 3.74 <10-300 
 
The combined group included the 28,864 cases and controls from the neuropathologically confirmed and unconfirmed groups. 
Association tests in a logistic regression model were conducted using clinical diagnosis as an outcome without adjustment (Model 1), with age and 
sex as covariates (Model 2), and with age, sex, and autopsy status as covariates (Model 3). 
For genotypic association tests, odds ratio (OR), 95% confidence interval (CI), and P value (P) for each APOE genotype compared to the APOE3/3 
genotype were calculated under a logistic regression model. 
For allelic association tests, OR, CI, and P associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2<2/3<3/3) and APOE4 allelic dose 




Supplementary Table 5. Number of Other Neuropathological Diagnoses for Each APOE Genotype 
 
APOE 
Congophilic Amyloid Angiopathy 
(CAA) 
 
Lewy Body Disease 
(LBD) 
 
Vascular Brain Injury 
(VBI) 
 Hippocampal Sclerosis (HS) 
with without  with without  with without  with without 
2/2 2 6  3 11  2 5  0 11 
2/3 56 68  43 167  75 68  14 142 
3/3 454 563  342 1054  482 583  104 1031 
2/4 51 22  30 36  33 44  8 66 
3/4 792 260  501 896  419 755  137 1058 
4/4 292 71  156 252  112 232  27 317 




Supplementary Table 6. Odds Ratios for Other Assessed Neuropathological Diagnoses 
 
APOE 
CAA  LBD  VBI  HS 
OR 95% CI P  OR 95% CI P  OR 95% CI P  OR 95% CI P 
Unadjusted              
   2/2 0.41 0.08 - 2.06 0.28  0.84 0.23 - 3.03 0.79  0.48 0.09 - 2.51 0.39  NC NC NC 
   2/3 1.02 0.7 - 1.49 0.91  0.79 0.56 - 1.13 0.20  1.33 0.94 - 1.89 0.11  0.98 0.54 - 1.76 0.94 
   2/4 2.87 1.72 - 4.81 6.3x10-5  2.18 1.38 - 3.45 8.2x10-4  0.91 0.57 - 1.45 0.68  1.20 0.56 - 2.57 0.64 
   3/4 2.73 2.29 - 3.25 2.3x10-28  1.72 1.46 - 2.03 8.9x10-11  0.67 0.57 - 0.8 4.5x10-6  1.28 0.98 - 1.68 0.07 
   4/4 5.10 3.83 - 6.8 1.6x10-27  1.91 1.51 - 2.41 7.2x10-8  0.58 0.45 - 0.75 4.0x10-5  0.84 0.54 - 1.31 0.45 
Adjusted for age and sex             
   2/2 0.42 0.08 - 2.1 0.29  0.86 0.23 - 3.12 0.81  0.50 0.09 - 2.74 0.43  NC NC NC 
   2/3 1.12 0.76 - 1.63 0.57  0.84 0.59 - 1.21 0.34  1.15 0.8 - 1.65 0.45  0.93 0.51 - 1.67 0.80 
   2/4 2.65 1.57 - 4.45 2.5x10-4  2.11 1.33 - 3.35 1.6x10-3  1.09 0.68 - 1.77 0.72  1.27 0.59 - 2.74 0.55 
   3/4 2.52 2.1 - 3.02 3.6x10-23  1.55 1.31 - 1.83 3.8x10-7  0.86 0.72 - 1.04 0.12  1.54 1.16 - 2.04 3.1x10-3 
   4/4 4.33 3.2 - 5.87 1.1x10-20  1.56 1.22 - 2.01 4.7x10-4  0.93 0.7 - 1.23 0.61  0.96 0.59 - 1.55 0.86 
Adjusted for age, sex, and neuropathological diagnosis of AD 
   2/2 0.95 0.16 - 5.55 0.96  1.67 0.43 - 6.49 0.46  0.67 0.12 - 3.71 0.65  NC NC NC 
   2/3 1.49 0.98 - 2.26 0.06  1.02 0.7 - 1.48 0.92  1.23 0.85 - 1.77 0.27  1.08 0.59 - 1.96 0.80 
   2/4 2.52 1.46 - 4.36 9.5x10-4  1.88 1.17 - 3.02 9.4x10-3  1.05 0.65 - 1.71 0.83  1.16 0.54 - 2.52 0.70 
   3/4 2.02 1.67 - 2.45 4.7x10-13  1.25 1.05 - 1.49 0.01  0.80 0.66 - 0.96 0.02  1.31 0.99 - 1.75 0.06 
   4/4 3.34 2.45 - 4.55 5.2x10-14  1.20 0.92 - 1.55 0.18  0.86 0.64 - 1.14 0.29  0.83 0.51 - 1.34 0.45 
 
CAA: congophilic amyloid angiopathy; LBD: Lewy body disease; VBI: vascular brain injury; HS: hippocampal sclerosis.    
Statistical tests for APOE2/2 and APOE4/4 genotypes compared to the APOE3/3 genotype were not converged (NC) by the extremely small 
number of persons with and without CAA, LBD, VBI, and HS. 
Since TDP-43 pathology and microinfarcts were not characterized in many of the participants, the impact of APOE genotypes on the presence 
or absence of those pathological diagnoses were not assessed.  
 
Supplementary Table 7. Other Neuropathological Diagnosis Odds Ratios with APOE2 and APOE4 Allelic Doses 
 
Model and Diagnosis 
APOE2 Allelic Dose  APOE4 Allelic Dose 
OR 95% CI P  OR 95% CI P 
Unadjusted     
CAA 0.93 0.67 - 1.31 0.68  2.43 2.13 - 2.76 1.1x10-39 
LBD 0.82 0.60 - 1.13 0.22  1.46 1.31 - 1.62 1.4x10-11 
VBI 1.20 0.87 - 1.65 0.27  0.73 0.65 - 0.83 3.3x10-7 
HS 0.85 0.49 - 1.48 0.58  1.02 0.85 - 1.23 0.83 
Adjusted for age and sex     
CAA 1.00 0.71 - 1.41 0.99  2.26 1.97 - 2.59 1.9x10-31 
LBD 0.86 0.62 - 1.19 0.36  1.32 1.17 - 1.47 2.6x10-6 
VBI 1.06 0.76 - 1.48 0.71  0.94 0.82 - 1.06 0.31 
HS 0.82 0.47 - 1.42 0.47  1.17 0.96 - 1.43 0.12 
Adjusted for age, sex, and neuropathological diagnosis of AD     
CAA 1.36 0.94 - 1.98 0.11  1.90 1.66 - 2.19 2.1x10-19 
LBD 1.07 0.76 - 1.50 0.71  1.13 1.01 - 1.28 0.04 
VBI 1.16 0.83 - 1.62 0.39  0.89 0.78 - 1.02 0.09 
HS 0.98 0.55 - 1.73 0.95  1.05 0.86 - 1.29 0.61 
 
CAA: congophilic amyloid angiopathy..LBD: Lewy body disease; VBI: vascular brain injury; HS: hippocampal sclerosis. 
 
Odds ratio (ORs), 95% confidence interval (CI), and P value (P) associated with APOE2 allelic dose in APOE4 non-carriers 
(APOE2/2<2/3<3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4>3/4>3/3) were generated using allelic association tests with 
an additive genetic model.  
Since TDP-43 pathology and microinfarcts were not assessed in all participants, the impact of APOE2 and APOE4 allelic doses on the 
presence or absence of those diagnoses were not assessed 
  
 
Supplementary Table 8. Summary and Association of CERAD Scores and Braak Stages  
APOE 
CERAD (Neuritic A Plaque) Score  Braak (Neurofibrillary Tangle [PHF Tau]) Stage 
N Mean±SD 
Unadjusted  Adjusted for AAD and Sex  
N Mean±SD 
Unadjusted  Adjusted for AAD and Sex 
BETA±SE P  BETA±SE P  BETA±SE P  BETA±SE P 
2/2 24 0.94±1.14 -1.04±0.30 5.6x10-4  -1.51±0.44 6.3E-04  16 2.38±1.71 -1.65±0.45 2.7x10-4  -1.51±0.44 6.3x10-4 
2/3 260 1.35±1.32 -0.63±0.09 1.9x10-11  -0.78±0.13 1.3E-09  227 3.17±1.95 -0.86±0.13 4.2x10-11  -0.78±0.13 1.3x10-9 
3/3 1911 1.98±1.24 Ref Ref  Ref Ref  1583 4.03±1.80 Ref Ref  Ref Ref 
2/4 127 2.40±0.99 0.42±0.14 1.9x10-3  0.84±0.05 1.5E-53  107 4.60±1.50 0.57±0.18 1.4x10-3  0.46±0.17 8.8x10-3 
3/4 2052 2.68±0.72 0.70±0.04 4.1x10-76  1.08±0.08 5.2E-37  1763 4.96±1.26 0.93±0.05 1.7x10-65  0.84±0.05 1.5x10-53 
4/4 549 2.88±0.42 0.90±0.06 7.8x10-51  -1.51±0.44 6.3E-04  633 5.28±0.93 1.25±0.08 1.1x10-51  1.08±0.08 5.2x10-37 
 
A: amyloid-; PHF: paired helical filament; AAD: Age at Death; AAD: age at death. CERAD Scores reflect the density of neuritic plaques: 0 
(none), 1 (sparse), 2 (moderate), and 3 (frequent); Braak Stages reflect the spatial distribution of neurofibrillary tangles: 0 (none), I-II 
(transentorhinal and entorhinal cortex), III-IV (hippocampal and neighboring limbic areas), and V-VI (neocortical areas). 
Ref: reference genotype to test association of each APOE genotype in a linear regression model Mean (Mean) and standard deviation (SD) for 
AAO, AAD, and AAE ranged from Mean-SD and Mean+SD, Mean±SD. 
Beta estimate (BETA), standard error (SE), and P value (P) for each APOE genotype compared to the APOE3/3 genotype as a reference (ref) 
were calculated under a linear regression model.  
Unadjusted: results from a linear regression for CERAD scores or Braak stages without adjusting for any covariates. 









Receiver Operating Characteristic (ROC) curves reflect the impact of APOE2 allelic dose (A) and APOE4 allelic dose (B) on the sensitivity and 
specificity to classify clinically diagnosed Alzheimer’s dementia cases and controls. ROC curves in the neuropathologically confirmed autopsy group 
were shown in red and those in the neuropathologically unconfirmed non-autopsy group are shown in black. As reflected by the Area Under the 
Curve (AUC), an indicator of classification accuracy, and their 95% confidence intervals, APOE2 and APOE4 allelic doses were each associated 
with significantly higher AUCs in the neuropathologically confirmed and unconfirmed groups; APOE2 allelic dose was associated with a significantly 




Supplementary Figure 2. CERAD Scores and Braak Stages for Each APOE Genotype in the Neuropathologically Confirmed Group.  
 
 
A.                                                                                            B. 
 
 
The means (mid-points) and standard deviations from the means (error bars) from CERAD (Neuritic A Plaque) scores (A) and Braak (Tau Tangle) 
stages (B) for each APOE genotype in Supplementary Table 8 were shown as the bar graphs. 
 
